Previous close | 8.55 |
Open | 8.72 |
Bid | 8.61 x 800 |
Ask | 8.63 x 900 |
Day's range | 8.60 - 8.95 |
52-week range | 2.60 - 9.84 |
Volume | |
Avg. volume | 777,446 |
Market cap | 922.268M |
Beta (5Y monthly) | -0.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.90 |
Earnings date | 09 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.03 |
LAVAL, Quebec, May 11, 2022--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today reported its financial and operating results for the first quarter ending March 31, 2022.
LAVAL, Quebec, May 02, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in San
LAVAL, Quebec, April 25, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that the Company’s management team will participate in multiple upcoming investor conferences.